---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-21-003880"
form_type: "8-K"
ticker: "CMMB"
cik: "0001534248"
company_name: "Chemomab Therapeutics Ltd."
filed_at: "2021-12-16T23:59:59+00:00"
generated_at: "2026-06-28T00:30:43.775589+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Chemomab CEO Dale Pfost expected to become chairman; Stephen Squinto resigns as chairman and director

## Summary
- Stephen Squinto resigns as chairman and director effective Dec 19, 2021; decision not due to any disagreement with company.
- CEO Dale Pfost, PhD expected to become chairman subject to shareholder vote in or around February 2022.
- Planned succession; Squinto's term was set to lapse by June 2022; transition accelerated to Dec 2021.
- Company advancing Phase 2 programs in primary sclerosing cholangitis, liver fibrosis; Phase 2 trial in systemic sclerosis planned.

## SEC filing metadata
- accession: 0001178913-21-003880
- form_type: 8-K
- ticker: CMMB
- cik: 0001534248
- company_name: Chemomab Therapeutics Ltd.
- filed_at: 2021-12-16T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534248/000117891321003880/0001178913-21-003880-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534248/000117891321003880/form8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-21-003880
- JSON: https://secwatch.observer/filing/0001178913-21-003880.json
- Plain text: https://secwatch.observer/filing/0001178913-21-003880.txt

## Key facts
- Executive change
  Stephen Squinto resigned as Chairman of the Board at Chemomab Therapeutics Ltd..
  - Action: resigned
  - Role: Chairman of the Board
  source text: On December 12, 2021, the Company and Mr. Squinto mutually agreed that Mr. Squinto’s resignation as the chairman of the Board will enter into effect on December 19, 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1534248/000117891321003880/0001178913-21-003880-index.htm
- Executive change
  Dale Pfost was appointed as Chairman of the Board at Chemomab Therapeutics Ltd..
  - Action: appointed
  - Role: Chairman of the Board
  source text: the nominating and governance committee and the Board each approved and recommended that the shareholders approve the appointment of Dr. Pfost as chairman of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1534248/000117891321003880/0001178913-21-003880-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.